// App-Quantinova.ai

O-13 : Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS

Researchers

Presenter

  • C. Serrano

Principal Investigators

  • M. Heinrich

  • S. George

  • J. Zalcberg

  • S. Bauer

  • H. Gelderblom

  • P. Schffski

  • R. Jones

  • S. Attia

  • G. D'Amato

  • P. Chi

  • P. Reichardt

  • J. Meade

  • V. Reichert

  • K. Shi

  • J. Blay

  • M. von Mehren

Medical Centers

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Oregon Health and Science University, Portland, Oregon, United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

  • University Hospital of Essen, Essen, Germany

  • Leiden University Medical Centre, Leiden, Netherlands

  • Leuven Cancer institute, Leuven, Belgium

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Mayo Clinic, Jacksonville, Jacksonville, Florida, United States

  • University of Miami Miller School of Medicine, Sylvester Cancer Center, Miami, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • HELIOS Klinikum Berlin-Buch, Berlin, Germany

  • Deciphera Pharmaceuticals, Waltham, United States

  • Universite Claude Bernard Lyon , EPHE, Lyon, France

  • Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Locations

  • Spain

  • United States

  • Australia

  • Germany

  • Switzerland

  • Belgium

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastrointestinal stromal tumor

Biomarkers

  • N/A

Drug/Treatment

  • Regorafenib

  • DCC-2618

  • Sunitinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved